Cliquez ici pour connaître notre offre FCPI 2014

The fast pace of innovation in IT offers compelling investment opportunities

Truffle Capital is a pioneer investor in the exciting field of Energy

Biotechnology has radically transformed medicine over the past 25 years


  • “ Truffle Capital is an efficient partner that enables us to improve our development strategy. Truffle’s reactivity in taking financial decisions is also key as PayTop is a French regulated financial firm. Truffle helps us benefit from its vision, its professional contacts but also enables us to meet our ambitions of becoming the leader in international innovative financial services. ”Paytop
    David Boucher, Chairman

Truffle Capital is an independent European venture capital firm

Truffle Capital is an independent venture capital firm investing in Europe. Established in 2001 and with close to €700 million under management and advisory as of the 30th June 2014, Truffle Capital is an important and independent European private equity firm, specialized in investments in spin-offs from companies active in the Energy, Information Technology and Life Sciences sectors. The firm is led by a team of three General Partners with decades of successful investment and entrepreneurial experience in both Europe and in the USA.

Backed by an investment team of international experts and an experienced support team, a total of 16 professionals, Truffle Capital aims to achieve superior financial returns by leveraging its industry knowledge, extensive network, and operational experience to identify business opportunities that match latent market needs.


10-2014

DEINOVE

15th October 2014 – DEINOVE TEAMS UP WITH MBI, PIONEER OF AFEX TECHNOLOGY, TO EVALUATE ITS PROCESS ON INDUSTRIAL BIOMASS

Pdf


+ read more
10-2014

NEOVACS

Le 10 octobre 2014 – NEOVACS INSTALLE SON NOUVEAU CONSEIL SCIENTIFIQUE INTERNATIONAL AUX ETATS-UNIS

Pdf


+ read more
10-2014

CARMAT

Le 09 octobre 2014 – CARMAT participe au 28e congrès annuel de l’EACTS à Milan (Italie)

Pdf


+ read more
10-2014

THERADIAG

Le 08 octobre 2014 – Le monitoring des biothérapies de la maladie de Crohn entraînerait une économie de plus de 130 millions d’euros en France

Pdf


+ read more